Topic Hub
5 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 5 of 5 clinical reviews.
A clinical overview of tesamorelin (Egrifta) compounding legality, FDA approval history, shortage designations, and what patients and providers need to know about access in 2026.
Read clinical reviewA detailed review of Egrifta (tesamorelin) FAERS adverse event reports, FDA label warnings, post-market surveillance data, and clinical trial safety findings for patients and clinicians.
Read clinical reviewA detailed review of all FDA label changes for Egrifta and Egrifta SV (tesamorelin) from 2020 through 2026, including updated warnings, post-marketing safety data, and clinical guidance.
Read clinical reviewA comprehensive review of Egrifta (tesamorelin) regulatory history, patent disputes, FDA labeling requirements, and post-market safety surveillance, with primary-source citations throughout.
Read clinical reviewA comprehensive review of tesamorelin's FDA approval history, prescribing label, post-market safety data, pipeline extensions, and emerging GHRH-analog research, reviewed by the HealthRX.com medical team.
Read clinical review